Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)Erythema multiforme following COVID-19 vaccination (BNT162b2)

被引：0
|
作者：
K. Wunderlich
T. Dirschka
机构：
[1] CentroDerm Klinik Wuppertal,Fakultät für Gesundheit
[2] Universität Witten-Herdecke,undefined
来源：
Der Hautarzt | 2022年 / 73卷 / 1期
关键词：
Erythema exsudativum multiforme; COVID-19-Impfung; BNT162b2, Tozinameran; Hypersensitivitätsreaktion; Interface-Dermatitis; Erythema multiforme major; Coronavirus disease 2019 vaccination; BNT162b2, tozinameran; Hypersensitivity reaction; Interface dermatitis;
D O I：
10.1007/s00105-021-04911-4
中图分类号：
学科分类号：
摘要：
Es wird über den Fall eines ausgeprägten Erythema exsudativum multiforme infolge einer COVID-19-Impfung berichtet. Die Effloreszenzen an Haut und Schleimhaut entwickelten sich 48 h nach der zweiten Dosis des mRNA-Impfstoffs BNT162b2 (Tozinameran, Comirnaty®). Unter der Anwendung glukokortikoidhaltiger Externa kam es innerhalb von 3 Wochen zu einer folgenlosen Abheilung.
引用
收藏
页码：68 / 70
页数：2
相关论文
共 50 条
  • [41] BNT162b2 mRNA COVID-19 Vaccine: First Approval
    Lamb, Yvette N.
    DRUGS, 2021, 81 (04) : 495 - 501
  • [42] Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine
    Lopez-Valle, Alba
    Falkenhain-Lopez, Daniel
    Arranz, Celia R.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (07) : 891 - 892
  • [43] Assessment of salivary antibody response to BNT162b2 mRNA COVID-19 vaccination
    Lapic, Ivana
    Segulja, Dragana
    Rogic, Dunja
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (09) : 5257 - 5259
  • [44] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Polack, Fernando P.
    Thomas, Stephen J.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Perez, John L.
    Perez Marc, Gonzalo
    Moreira, Edson D.
    Zerbini, Cristiano
    Bailey, Ruth
    Swanson, Kena A.
    Roychoudhury, Satrajit
    Koury, Kenneth
    Li, Ping
    Kalina, Warren V.
    Cooper, David
    Frenck, Robert W., Jr.
    Hammitt, Laura L.
    Tureci, Ozlem
    Nell, Haylene
    Schaefer, Axel
    Unal, Serhat
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27): : 2603 - 2615
  • [45] Second dose of COVID-19 vaccination in immediate reactions to the first BNT162b2
    Rosa Duque, Jaime S.
    Leung, Daniel
    Au, Elaine Y. L.
    Lau, Yu-Lung
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (01)
  • [46] Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
    Kazuyuki Saito
    Taro Shimizu
    Katsue Suzuki-Inoue
    Tatsuhiro Ishida
    Yoshiaki Wada
    Neurological Sciences, 2021, 42 : 4433 - 4435
  • [47] Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
    Dogan, Mustafa
    Yilmaz, Berna
    ACTA PHARMACEUTICA, 2023, 73 (02) : 257 - 268
  • [48] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Wang, Xiang
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1577 - 1578
  • [49] Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine
    Tumminia, Andrea
    Romano, Marcello
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02): : 191 - 191
  • [50] BNT162b2 mRNA COVID-19 Vaccine: First Approval
    Yvette N. Lamb
    Drugs, 2021, 81 : 495 - 501
12345